Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2018-06-05 Share Issue/Capital Cha…
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Informations mensuelles relatives au nombre total de droits de vote et d'actions' (Monthly information relating to the total number of voting rights and shares) and explicitly references Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. It provides a table detailing the number of shares and total voting rights as of a specific date (31/05/2018). This structure is characteristic of mandatory periodic disclosures regarding share capital and voting rights, which often fall under general regulatory announcements or specific share/capital change notifications. Given the options, this is a specific regulatory filing concerning share structure and voting rights, which is not explicitly covered by DVA (Voting Results) or SHA (Share Issue/Capital Change, which usually implies a transaction). Since it is a mandatory monthly disclosure of voting rights, it fits best under the general 'Regulatory Filings' (RNS) category as a specific regulatory update that doesn't match the other precise definitions, although it relates to share capital. However, upon re-evaluation against the provided definitions, there is no specific code for 'Monthly Voting Rights Disclosure'. It is a regulatory filing, making RNS the most appropriate fallback. It is not a DVA (which is about results of a vote), nor is it a standard SHA (which usually announces a change/issue). Therefore, RNS is the best fit as a general regulatory filing.
2018-06-05 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated May 31, 2018, announcing the launch of a new product, ENDOZYME® II GO, for endotoxin detection in the pharmaceutical industry. It details the product's features, the technology used (rFC), and quotes management. This type of announcement, focusing on a specific business development, product launch, or general corporate news that isn't a mandatory financial filing (like 10-K, ER, or IR), typically falls under general regulatory announcements or news releases. Since it is not a specific financial report, management change, dividend notice, or earnings release, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory/corporate news releases that don't fit other specific codes. The document length (5011 chars) is substantial enough to be a standalone release, not just a brief announcement of a report.
2018-05-31 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated May 31, 2018, announcing the launch of a new product, ENDOZYME® II GO, for endotoxin testing. It details the product features, market context (animal-free testing), and quotes management. This type of announcement, focusing on a new product or business development rather than periodic financial results (like 10-K or ER) or specific regulatory events (like DIRS or DIV), typically falls under general corporate news or regulatory filings. Since it is a specific product launch announcement and not a standard financial report, it does not fit well into the primary financial categories. Given the options, it is a general corporate announcement. It is not a Call Transcript (CT), Earnings Release (ER), or Interim Report (IR). It is too detailed for a simple Fund Factsheet (FS). It is best classified as a general Regulatory Filing (RNS) as it is a public announcement of a significant business development, or potentially a general Investor Relations document, but RNS serves as the best general corporate announcement fallback when specific categories like ER or DEF 14A do not apply. Given the context of a product launch press release, RNS is the most appropriate general category.
2018-05-31 English
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 98% confidence The document is titled "DESCRIPTIF DU PROGRAMME DE RACHAT D'ACTIONS" (Description of the Share Buyback Program) and details the authorization, maximum price, objectives (liquidity, employee stock plans, capital reduction), and duration of a share repurchase program authorized by the 'Assemblée générale mixte' (Combined General Meeting). This content directly relates to the company's actions regarding its own shares, specifically repurchases. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS). Although it describes a program authorized by a general meeting, the core subject is the buyback activity itself, not the meeting results (DVA) or the general capital structure change (SHA).
2018-05-17 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223- 16 du règlement général de l'Autorité des marchés financiers". This explicitly refers to a monthly disclosure regarding the total number of voting rights and shares, mandated by French commercial code and AMF regulations. This type of regular disclosure, which is not a full financial report (10-K or IR) but a specific regulatory update on share structure/voting rights, fits best under the general 'Regulatory Filings' category (RNS) or potentially a specific category if one existed for voting rights updates. Since there is no specific code for 'Monthly Voting Rights Disclosure', and it is a mandatory regulatory filing, RNS is the most appropriate fallback. The document is short and contains specific data points (date, number of shares, number of voting rights).
2018-05-03 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated May 2nd, 2018, announcing that biomarkers used in the NEPHROCHECK test have been included in consensus guidelines from ERAS® Cardiac Surgery. It details the significance of this inclusion, references recent studies, and provides background information on the companies involved (bioMérieux, Astute Medical). This format—a news announcement about a development, often including quotes and background sections—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management discussion (MDA), and it is an announcement of news rather than a formal regulatory filing like a DIRS or DIV, it fits best as an Earnings Release (ER) if it were tied to financial results, or more generally, a Regulatory Filing (RNS) if it's just corporate news. Given the content is a significant corporate/clinical development announcement, and it is not explicitly an earnings report, RNS is a strong candidate. However, press releases announcing major clinical/guideline updates are often categorized under ER if they are issued around reporting periods, or RNS if they are purely informational. Since this is a news announcement about a clinical/guideline development, and not a formal SEC filing, RNS (Regulatory Filings/General Announcement) is the most appropriate general category for non-standard corporate news releases that don't fit the other specific codes.
2018-05-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.